keyword
MENU ▼
Read by QxMD icon Read
search

Ebv ptld

keyword
https://www.readbyqxmd.com/read/29755021/a-single-center-experience-of-post-transplant-lymphoproliferative-disorder-ptld-cases-after-pediatric-liver-transplantation-incidence-outcomes-and-association-with-food-allergy
#1
Zeren Barış, Figen Özçay, Özlem Yılmaz Özbek, Nihan Haberal, Faik Sarıalioğlu, Mehmet Haberal
BACKGROUND/AIMS: We evaluated our 16-year single-center experience of pediatric post-transplant lymphoproliferative disorder (PTLD) cases who underwent liver transplantation between 2001 and 2017. MATERIALS AND METHODS: Of the 236 pediatric patients who underwent liver transplantation between 2001 and 2017, the clinical and laboratory data of eight patients diagnosed with PTLD were reviewed. The pre-transplant Epstein-Barr virus (EBV) status of 172 patients was also recorded...
May 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29754771/epstein-barr-virus-specific-cytokine-induced-killer-cells-for-treatment-of-epstein-barr-virus-related-malignant-lymphoma
#2
Lisa-Marie Pfeffermann, Verena Pfirrmann, Sabine Huenecke, Melanie Bremm, Halvard Bonig, Hans-Michael Kvasnicka, Thomas Klingebiel, Peter Bader, Eva Rettinger
BACKGROUND: Prolonged immunosuppression or delayed T-cell recovery may favor Epstein-Barr virus (EBV) infection or reactivation after allogeneic hematopoietic stem cell transplantation (HSCT), which can lead to post-transplant lymphoproliferative disease (PTLD) and high-grade malignant B-cell lymphoma. Cytokine-induced killer (CIK) cells with dual specific anti-tumor and virus-specific cellular immunity may be applied in this context. METHODS: CIK cells with EBV-specificity were generated from peripheral blood mononuclear cells (PBMCs), expanded in the presence of interferon-γ, anti-CD3, interleukin (IL)-2 and IL-15 and were pulsed twice with EBV consensus peptide pool...
May 10, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29745058/post-transplant-lymphoproliferative-disorder-in-pediatric-intestinal-transplant-recipients-a-literature-review
#3
REVIEW
Kaitlin Stanley, Erika Friehling, Sarangarajan Ranganathan, George Mazariegos, Linda M McAllister-Lucas, Rakesh Sindhi
Intestinal transplantation is a successful treatment for children with intestinal failure, but has many potential complications. PTLD, a clinically and histologically diverse malignancy, occurs frequently after intestinal transplantation and can be fatal. The management of this disease is particularly challenging. The rejection-prone intestinal allograft requires high levels of immunosuppression, a precondition for PTLD. While EBV infection clearly plays a role in disease pathogenesis, the relatively naïve immune system of children is another likely contributor...
May 10, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29743796/increased-incidence-of-post-transplant-lymphoproliferative-disorder-in-autoimmune-liver-disease-an-irish-national-experience
#4
Ahmed Abu-Shanab, Yasser Ged, Naeem Ullah, Diarmaid Houlihan, Aiden McCormick
Background: Post-Transplant Lymphoproliferative Disorder (PTLD) is a well-recognized complication post solid organs transplant. PTLD represents a broad spectrum of abnormalities ranging from an infectious mononucleosis like illness to malignant lymphoma. Methods: A retrospective study was performed by collecting data of orthotopic liver transplant (OLT) patients in the National Liver Unit in Ireland from December 1993 to December 2014. Data was analyzed to identify PTLD patients and determine their demographic details, the indication for liver transplant, presenting symptoms, immunosuppression regimens, Epstein"Barr virus (EBV) status and PTLD outcome...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29661453/late-onset-post-transplantation-central-nervous-system-lymphoproliferative-disorder-case-report
#5
J Rego Silva, R A Macau, H Oliveira Coelho, F Camelo, P Cruz, A Mateus, A Oliveira, C Oliveira, A Ramos
Post-transplantation lymphoproliferative disorder (PTLD) is a heterogeneous group of conditions that complicate organ transplantation and are due to immunosuppression. Central nervous system (CNS)-PTLD is rare but its incidence is increasing. It often occurs late and is associated with kidney transplantation and Epstein-Barr virus (EBV) infection. Outcomes are poor. We present the case of a 77-year-old white male who received a cadaveric kidney transplant in 2003. Maintenance immunosuppression consisted of mycofenolate mofetil (MMF), cyclosporine, and prednisolone...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29659047/the-changing-face-of-adult-posttransplant-lymphoproliferative-disorder-changes-in-histology-between-1999-2013
#6
Donald E Tsai, Stephen Bagley, Ran Reshef, Abraham Shaked, Roy D Bloom, Vivek Ahya, Lee Goldberg, Albert Chung, Fotini Debonera, Stephen J Schuster, Scott F Huntington
Posttransplant lymphoproliferative disorder (PTLD) typically presents with either polymorphic or monomorphic histology. While both are the end result of immunosuppressive therapies, their origins are felt to be different with different prognoses and responsiveness to therapy, resulting in two different malignancies. We attempted to confirm reports suggesting that the relative frequency of these two histologies is shifting over time. We analyzed 3040 adult PTLD cases in the UNOS OPTN database from 1999 to 2013...
April 16, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29642526/construction-and-characterization-of-a-humanized-anti-epstein-barr-virus-gp350-antibody-with-neutralizing-activity-in-cell-culture
#7
Jerome E Tanner, Jing Hu, Caroline Alfieri
Acute Epstein-Barr virus (EBV) infection in immunosuppressed transplant patients can give rise to a malignant B-cell proliferation known as post-transplant lymphoproliferative disease (PTLD). The EBV major virion surface glycoprotein (gp)350 is a principal target of naturally occurring neutralizing antibodies and is viewed as the best target to prevent acute infection and PTLD in at-risk transplant recipients. We have constructed a humanized (hu) version of the murine anti-gp350 neutralizing monoclonal antibody 72a1...
April 9, 2018: Cancers
https://www.readbyqxmd.com/read/29620685/ebv-ptld-adenovirus-and-cmv-in-pediatric-allogeneic-transplants-with-alemtuzumab-as-part-of-pretransplant-conditioning-a-retrospective-single-center-study
#8
Margaret C Cupit-Link, Amulya Nageswara Rao, Deepti M Warad, Vilmarie Rodriguez, Shakila Khan
The risk of viral infections and reactivation occurring in the setting of pediatric allogeneic hematopoietic stem cell transplantation is a concern in the pediatric patient, especially with the use of Alemtuzumab (Campath) as a conditioning agent. The purpose of this study was to determine the incidence of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV-PTLD), cytomegalovirus (CMV), and adenovirus among pediatric recipients of alemtuzumab at our institution. We found that EBV-PTLD occurred in 2...
April 3, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29615296/reexamining-post-transplant-lymphoproliferative-disorders-newly-recognized-and-enigmatic-types
#9
REVIEW
Nadine Aguilera, Alejandro A Gru
Post-transplant lymphoproliferative disorders (PTLD) are a known risk for both solid organ transplant and stem cell transplant recipients. Overall transplant recipients have a six fold increase in risk for developing any kind of non-Hodgkin lymphoma and PTLDs occur in up to 10% of SOT recipients. Several new entities have been accepted or renamed in the 2018 update of the WHO classification of tumors of hematopoietic and lymphoid neoplasms, including florid follicular hyperplasia and extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT-lymphoma) (excluding common locations such as stomach and salivary gland)...
March 3, 2018: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/29580864/epstein-barr-virus-dnaemia-monitoring-for-the-management-of-post-transplant-lymphoproliferative-disorder
#10
Amit Kalra, Cameron Roessner, Jennifer Jupp, Tyler Williamson, Raymond Tellier, Ahsan Chaudhry, Faisal Khan, Minakshi Taparia, Victor H Jimenez-Zepeda, Douglas A Stewart, Andrew Daly, Jan Storek
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of allogeneic hematopoietic cell transplantation (HCT). Epstein-Barr virus (EBV) reactivation (detectable DNAemia) predisposes to the development of PTLD. METHODS: We retrospectively studied 306 patients monitored for EBV DNAemia after Thymoglobulin-conditioned HCT to determine the utility of the monitoring in the management of PTLD. DNAemia was monitored weekly for ≥12 weeks post-transplantation...
May 2018: Cytotherapy
https://www.readbyqxmd.com/read/29485513/the-changing-epidemiology-of-posttransplant-lymphoproliferative-disorder-in-adult-solid-organ-transplant-recipients-over-30-years-a-single-center-experience
#11
Anthea C Peters, Michael S Akinwumi, Carlos Cervera, Curtis Mabilangan, Sunita Ghosh, Raymond Lai, Marco Iafollo, Karen Doucette, Jutta K Preiksaitis
BACKGROUND: Posttransplant lymphoproliferative disorders (PTLD) are a complication of solid organ transplantation (SOT) associated with Epstein-Barr virus (EBV). METHODS: We analyzed the incidence of and risk factors for PTLD among adult SOT recipients at our center over 30 years (1984-2013). We also compared PTLD incidence before and after a prevention strategy of EBV viral load monitoring in EBV serology mismatched patients was adopted in 2001 (ie transplant era 1 (1983-2001) vs era 2 (2002-13))...
February 26, 2018: Transplantation
https://www.readbyqxmd.com/read/29467338/tcr-mimic-bispecific-antibodies-targeting-lmp2a-show-potent-activity-against-ebv-malignancies
#12
Mahiuddin Ahmed, Andres Lopez-Albaitero, Dmitry Pankov, Brian H Santich, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang, Aisha N Hasan, Annamalai Selvakumar, Richard J O'Reilly, Cheng Liu, Nai-Kong V Cheung
EBV infection is associated with a number of malignancies of clinical unmet need, including Hodgkin lymphoma, nasopharyngeal carcinoma, gastric cancer, and posttransplant lymphoproliferative disease (PTLD), all of which express the EBV protein latent membrane protein 2A (LMP2A), an antigen that is difficult to target by conventional antibody approaches. To overcome this, we utilized phage display technology and a structure-guided selection strategy to generate human T cell receptor-like (TCR-like) monoclonal antibodies with exquisite specificity for the LMP2A-derived nonamer peptide, C426LGGLLTMV434 (CLG), as presented on HLA-A*02:01...
February 22, 2018: JCI Insight
https://www.readbyqxmd.com/read/29435138/personalized-adoptive-immunotherapy-for-patients-with-ebv-associated-tumors-and-complications-evaluation-of-novel-naturally-processed-and-presented-ebv-derived-t-cell-epitopes
#13
Maren Bieling, Sabine Tischer, Ulrich Kalinke, Rainer Blasczyk, Søren Buus, Britta Maecker-Kolhoff, Britta Eiz-Vesper
Morbidity and mortality of immunocompromised patients are increased by primary infection with or reactivation of Epstein-Barr virus (EBV), possibly triggering EBV+ post-transplant lymphoproliferative disease (PTLD). Adoptive transfer of EBV-specific cytotoxic T cells (EBV-CTLs) promises a non-toxic immunotherapy to effectively prevent or treat these complications. To improve immunotherapy and immunomonitoring this study aimed at identifying and evaluating naturally processed and presented HLA-A*03:01-restricted EBV-CTL epitopes as immunodominant targets...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29432665/post-transplant-lymphoproliferative-disorder-prevention-new-light-on-the-horizon
#14
COMMENT
Thomas Fehr
No abstract text is available yet for this article.
May 2018: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/29430795/pediatric-renal-transplantation-a-retrospective-single-center-study-on-epidemiology-and-morbidity-due-to-ebv
#15
A Laurent, A Klich, P Roy, B Lina, B Kassai, J Bacchetta, P Cochat
Pediatric R-Tx patients are at high risk of developing EBV primary infection. Although high DNA replication is a risk factor for PTLD, some patients develop PTLD with low viral load. In this retrospective single-center study including all pediatric patients having received R-Tx (2003-2012 period), we aimed to identify risk factors for uncontrolled reactions to EBV (defined as the presence of a viral load >10 000 copies/mL or PTLD). A Cox proportional hazard model was performed. A total of 117 patients underwent R-Tx at a mean age of 9...
May 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29411474/epidemiology-and-outcome-of-chronic-high-epstein-barr-viral-load-carriage-in-pediatric-kidney-transplant-recipients
#16
Masaki Yamada, Christina Nguyen, Paul Fadakar, Armando Ganoza, Abhinav Humar, Ron Shapiro, Marian G Michaels, Michael Green
The development of EBV infection and PTLD is normally associated with a high EBV viral load in peripheral blood. Observations have previously identified existence of a CHL carrier state that demonstrated variable outcomes based upon the organ which was transplanted. Data defining the incidence and outcome of CHL in pediatric KTx are not well described. The charts of children undergoing isolated KTx at Children's Hospital of Pittsburgh between January 2000 and December 2014 were retrospectively reviewed. EBV loads in the peripheral blood were routinely measured as part of surveillance protocols at our center...
May 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29391313/post-transplant-malignancies-in-pediatric-liver-transplant-recipients-experience-of-two-centers-in-turkey
#17
Miray Karakoyun, Şebnem Önen, Maşallah Baran, Murat Çakır, Çiğdem Ömür Ecevit, Murat Kılıç, Mehmet Kantar, Serap Aksoylar, Funda Özgenç, Sema Aydoğdu
BACKGROUND/AIMS: A liver transplant is the preferred treatment for patients with end-stage liver disease, as it usually results in longterm survival. However, due to the use of chronic immunosuppressive therapy, which is necessary to prevent rejection, de novo cancer is a major risk after transplantation. The aim of this study was to assess the incidence of post-transplant malignancies in children after liver transplantations. MATERIALS AND METHODS: The study group consisted of 206 liver transplant recipients, with no history of cancer, including hepatocellular carcinoma, in two liver transplantation centers in Turkey between 1997 and 2015...
January 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29388302/cytotoxic-t-lymphocyte-therapy-for-post-transplant-lymphoproliferative-disorder-after-solid-organ-transplantation-in-children
#18
Fang Kuan Chiou, Sue V Beath, Gwen M Wilkie, Mark A Vickers, Bruce Morland, Girish L Gupte
EBV-CTL immunotherapy targets EBV antigens expressed by tumor cells in PTLD. Data on outcome of EBV-CTL in pSOT patients are limited. The aim of the study is to describe our experience with allogeneic, third-party EBV-CTL for the treatment of PTLD in pSOT patients in a single tertiary center. Retrospective review was performed of all pSOT patients who received EBV-CTL for PTLD. PTLD was diagnosed using World Health Organization histologic criteria. EBV-CTLs were derived from human leukocyte antigen-typed, EBV-seropositive third-party donors, and cryopreserved and maintained by an accredited national blood transfusion service...
March 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29380181/classical-hodgkin-lymphoma-type-post-transplant-lymphoproliferative-disorder-in-a-kidney-transplant-recipient-a-diagnostic-pitfall
#19
Taro Mohri, Yoshihiro Ikura, Asako Hirakoso, Masashi Okamoto, Masakatsu Hishizawa, Akifumi Takaori-Kondo, Seiichi Kato, Shigeo Nakamura, Kai Yoshimura, Hidetoshi Okabe, Yasuhiro Iwai
We report a case of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder (HL-PTLD) after kidney transplantation to highlight the difficulty of distinguishing this disorder from Hodgkin lymphoma-like PTLD (HL-like PTLD). Through this case report and literature review, we seek to clarify definitive pathologic features to differentiate these two conditions. A 38-year-old male kidney transplant recipient who had been receiving immunosuppressants was admitted to our hospital with unidentified high fever...
January 29, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29342279/incidence-and-predictors-of-post-transplant-lymphoproliferative-disease-after-kidney-transplantation-during-adulthood-and-childhood-a-registry-study
#20
Anna Francis, David W Johnson, Armando Teixeira-Pinto, Jonathan C Craig, Germaine Wong
Background: Differences in the epidemiology of post-transplant lymphoproliferative disease (PTLD) between adult and paediatric kidney transplant recipients remain unclear. Methods: Using the Australian and New Zealand Dialysis and Transplant Registry (1963-2015), the cumulative incidences of PTLD in children (age <20 years) and adults were calculated using a competing risk of death model and compared with age-matched population-based data using standardized incidence ratios (SIRs)...
January 12, 2018: Nephrology, Dialysis, Transplantation
keyword
keyword
9384
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"